Inclusion Criteria:

- patients who have completed 4 infusions of catumaxomab in the CASIMAS study

- age >= 18 years

- Karnofsky index >= 60 %

- patients with malignant ascites requiring their first therapeutic ascites
paracentesis after at least 60days following last catumaxomab infusion in the CASIMAS
study

- Patients where standard therapy is either not available or no longer feasible

Exclusion Criteria:

- acute or chronic infection

- concomitant treatment with investigational products other than catumaxomab, cancer,
chemo- or radiotherapy

- previous treatment with entirely murine monoclonal antibodies other than catumaxomab

- liver metastases with volume >70 % of liver metastasized tissue